She even suggested I consider a switch to a brand new med that was a combination of a GLP-1 receptor agonist + GIP receptor agonist
It directly stimulates pro-opiomelanocortin/cocaine-and-amphetamine-regulated transcript (POMC/CART) neurons and indirectly inhibits neuropeptide-Y/agouti-related protein (NPY/AgRP) neurons through GABA neurotransmission, reducing appetite and promoting weight loss [40]
The training covers obesity science, nutritional interventions, pharmacotherapy, and behavioral strategies solidifying the legitimacy of psychiatrists treating weight as part of holistic care
Highest dose, obesity trial obesity-plus-diabetes trial (treatment-policy estimand): Semaglutide: 14.9% (STEP 1) 9.6% (STEP 2), a 5.3 point gap Tirzepatide: 20.9% (SURMOUNT-1) 14.7% (SURMOUNT-2), a 6.2 point gap Retatrutide: 25.0% (TRIUMPH-1) 20.8% (TRIUMPH-2 only efficacy-estimand currently reported so true gap is larger) It's still unclear the reason why we observe less weight loss in those with T2D
If you miss by more than 3 days, skip that week and take the next scheduled dose
Wernickes encephalopathy: New clinical settings and recent advances in diagnosis and management
.webp)
